Literature DB >> 20011564

Accomplishments in 2008 in the treatment of metastatic pancreatic cancer.

Volker Heinemann1, Philip A Philip, Uwe Pelzer.   

Abstract

Overview of the DiseaseIncidencePrognosisCurrent Treatment StandardsCytotoxic TherapyTargeted TherapySalvage TherapyAccomplishments or Lack of AccomplishmentsTherapySalvage TherapyBiomarkersApplication of the AccomplishmentsFuture DirectionsCurrent Basic ResearchOngoing Clinical StudiesMajor Obstacles to Progress in Drug DevelopmentGemcitabine PlatformChoice of Molecular TargetsPatient Selection.

Entities:  

Year:  2009        PMID： 20011564      PMCID： PMC2791391     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  19 in total

1.  An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.

Authors:  Georg Feldmann; Volker Fendrich; Karen McGovern; Djahida Bedja; Savita Bisht; Hector Alvarez; Jan-Bart M Koorstra; Nils Habbe; Collins Karikari; Michael Mullendore; Kathleen L Gabrielson; Rajni Sharma; William Matsui; Anirban Maitra
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

Review 2.  Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions.

Authors:  Henry Q Xiong; Kelli Carr; James L Abbruzzese
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

4.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

Review 5.  Pancreatic cancer stem cells.

Authors:  Cheong J Lee; Joseph Dosch; Diane M Simeone
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

6.  TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition.

Authors:  H Jung; K P Lee; S J Park; J H Park; Y-S Jang; S-Y Choi; J-G Jung; K Jo; D Y Park; J H Yoon; J-H Park; D-S Lim; G-R Hong; C Choi; Y-K Park; J W Lee; H J Hong; S Kim; Y W Park
Journal:  Oncogene       Date:  2007-10-29       Impact factor: 9.867

7.  Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.

Authors:  Jennifer L Dembinski; Stefan Krauss
Journal:  Clin Exp Metastasis       Date:  2009-05-07       Impact factor: 5.150

8.  Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials.

Authors:  J P Neoptolemos; D D Stocken; C Tudur Smith; C Bassi; P Ghaneh; E Owen; M Moore; R Padbury; R Doi; D Smith; M W Büchler
Journal:  Br J Cancer       Date:  2009-01-06       Impact factor: 7.640

9.  Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

Authors:  Volker Heinemann; Stefan Boeck; Axel Hinke; Roberto Labianca; Christophe Louvet
Journal:  BMC Cancer       Date:  2008-03-28       Impact factor: 4.430

10.  A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells.

Authors:  Ulrike Burk; Jörg Schubert; Ulrich Wellner; Otto Schmalhofer; Elizabeth Vincan; Simone Spaderna; Thomas Brabletz
Journal:  EMBO Rep       Date:  2008-05-16       Impact factor: 8.807
View more
  2 in total

Review 1.  Therapeutic antibodies for the treatment of pancreatic cancer.

Authors:  Patrick Chames; Brigitte Kerfelec; Daniel Baty
Journal:  ScientificWorldJournal       Date:  2010-06-15

2.  Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial.

Authors:  Uwe Pelzer; Andreas Hilbig; Jens M Stieler; Marcus Bahra; Marianne Sinn; Bernhard Gebauer; Bernd Dörken; Hanno Riess
Journal:  BMC Cancer       Date:  2014-03-19       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.